Aeed MZ,Ibrahim IK,Elamin HA,Ali EW .2014 .Coexistence of Jak2v617f mutation and philadelphia chromosome in sudanese patients with chronic myeloid leukemia. AJRC., 2(12) : 128-140.
Al-Kaabi MHAA,Al-Obaidy YGY,Sabir SF,AlKadmy MS SF .2013 .Incidence of Jak2 V617f mutation in Iraqi patients with Philadelphia positive Cml. Mintage J. Pharm. Med. Sci., 2(4) : 10-12.
Antonioli E,Carobbio A,Pieri L,Pancrazzi A,Guglielmelli P,Delaini F,Ponziani V,Bartalucci N,Tozzi L,Bosi A .2010 .Hydroxyurea does not appreciably reduce Jak2 V617f allele burden in patients with polycythemia vera or essential thrombocythemia. , 95(8) : 1435-1438.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz M J,Le Beau MM,Bloomfield CD,Cazzola M .2016 .The 2016 revision to the World Health Organization Classification of myeloid neoplasms and acute leukemia. Blood, 127(20) : 2391-2405.
Azonbakin S,Houssou B,Azannai I,Awede B,Massi R,Adjagba M,Agbalinsou A,Anani L,Darboux R,Gangbo F R .2018 .The Jak2 V617f mutation in chronic myeloid leukaemia within a bcr-abl positive cohort of beninese patients. Int. Blood Res. Rev., 8(1) : 1-6.
Baccarani M,Deininger MW,Rosti G,Hochhaus A,Soverini S,Apperley JF,Cervantes F,Clark RE,Cortes JE,Guilhot F JE .2013 .European leukemianet recommendations for the management of chronic myeloid leukemia: 2013. , 122(6) : 872-884.
Dreiling Bader G,B Bader G .2019 .Concurrent Jak2-positive myeloproliferative disorder and chronic Myelogenous leukemia: A novel entity? A case report with review of the literature. J. Investig. Med. High Impact Case Rep.,, 7 : 1-5.
Beillard E,Pallisgaard N,Van Der Velden V,Bi W,Dee R,Delabesse E,Macintyre E,Gottardi E,Saglio E,G E,Pcr E .2003 .-A Europe against cancer program. Leukemia, 17(12) : 2474-2486.
Bench AJ,White HE,Foroni L,Godfrey AL,Gerrard G,Akiki S,Awan A,Carter I,Goday‐Fernandez A,Langabeer SE .2013 .Molecular diagnosis of the myeloproliferative neoplasms: UK Guidelines for the detection of Jak 2 V 617 F and other relevant mutations. br. J. Haematol, 16091 : 25-34.
Frikha R,Turki F,Kassar O,Elloumi M,Kamoun H M,Oncol M .2021 .Co-Existence Of Bcr-Abl and Jak2v617f mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation? J. , 27(7) : 1784-1789.
Gabert J,Beillard E,Van Der Velden V,Bi W,Grimwade D,Pallisgaard N,Barbany G,Cazzaniga G,Cayuela JM,Cave H JM .2003 .Standardization and quality control studies of 'Real-Time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in LeukemiaA Europe against cancer program. Leukemia, 17(12) : 2318-2357.
Harrison C,Kiladjian JJ,Al-Ali HK,Gisslinger H,Waltzman R,Stalbovskaya V,Mcquitty M,Hunter DS,Levy R,Knoops L R .2012 .Jak inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Eng. J. Med, 366(9) : 787-798.
Inami M,Inokuchi K,Okabe M,Kosaka F,Mitamura Y,Yamaguchi H,Dan K H .2007 .Polycythemia associated with the Jak2v617f mutation emerged during treatment of chronic myelogenous leukemia. Leukemia, 21 : 1103-1104.
Inami M,Yamaguchi H,Hasegawa S,Mitamura Y,Kosaka F,Kobayashi A,Kimura S,Dan K,Inokuchi K K .2008 .Analysis of the exon 12 and 14 mutations of the Jak 2 gene in Philadelphia chromosome-positive leukemia. Leukemia, 22 : 216.
Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Leibundgut EO,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G .2013 .V617f-Associated myeloproliferative neoplasms: A joint European Leukemianet/ Mpn&Mpnr-Euronet (Cost Action Bm0902) Study. , 27(10) : 2032-2039.
Kim B,Lee KT,Yoon YA,Choi YJ .2020 .Clinical significance of myeloproliferative neoplasms with Jak2v617f mutations and major Bcr-Abl1 Translocations: A literature review with case presentation. Blood Res., 55(1) : 62-65.
Lewandowski K,Gniot M,Wojtaszewska M,Kanduła Z,Becht R,Paczkowska E,Medras E,Wasilewska E,Iwoła M .2018 .Coexistence of Jak2 or calr mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Int. J. Lab. Hematol., 40(3) : 366-371.
Lorenzo M,Grille S,Stevenazzi M .2020 .Emergence of Bcr-Abl1 chronic myeloid leukemia in a Jak2-V617f polycythemia vera. J. Hematol., 9(1) : 23-29.
Martin-Cabrera P,Haferlach C,Kern W,Schnittger S,Haferlach T .2017 .Bcr-Abl1-Positive and Jak2 V617f-Positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br. J. Haematol., 176(1) : 135-139.
Mirza I,Frantz C,Clarke G,Voth AJ,Turner R .2007 .Transformation of polycythemia vera to chronic myelogenous leukemia. Arch. Pathol. Lab. Med, 131(11) : 1719-1724.
Soderquist CR,Ewalt MD,Czuchlewski DR,Geyer JT,Rogers HJ,Hsi ED,Wang SA,Bueso-Ramos CE,Orazi A,Arber DA .2018 .Myeloproliferative neoplasms with concurrent Bcr-Abl1 translocation and Jak2 V617f mutation: A multi-institutional study from the bone marrow pathology group. Modern Pathology, 31(5) : 690-704.
Sweet K,Hazlehurst L,Sahakian E,Powers J,Nodzon L,Kayali F,Hyland K,Nelson A,Pinilla-Ibarz J .2018 .A Phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res, 74 : 89-96.
Tabassum N,Saboor M,Ghani R,Moinuddin M .2014 .Frequency of Jak2 V617f mutation in patients with Philadelphia positive chronic myeloid leukemia in Pakistan. Pak. J. Med. Sci., 30(1) : 185-188.
Tefferi A,Pardanani A .2015 .Myeloproliferative neoplasms: A contemporary review. JAMA Oncol, 1(1) : 97-105.
Toni LS,Garcia AM,Jeffrey DA,Jiang X,Stauffer BL,Miyamoto SD,Sucharov CC .2018 .Optimization of phenol-chloroform RNA extraction. Methodsx, 5 : 599-608.
Valikhani A,Poopak B,Ferdowsi S,Azizi Tabesh G,Ghaffari SH,Saraf Kazeruoni E,Rezaei N,Farshchi A,Amirizadeh N A .2017 .Asxl1 and Jak2v617f gene mutation screening in Iranian patients with chronic myeloid leukemia. Asia Pac. J. Clin. Oncol., 13(2) : E41-E47.
Zaen-Al-Abideen Pahore TS,Shamsi MT,Tasneem Farzana SH,Nadeem M,Ahmad M,Naz A .2011 .Jak2v617f mutation in chronic myeloid leukemia predicts early disease progression. J Coll Phys Surg Pak, 21(8) : 472-475.
Zhou A,Knoche E,Engle E,Fisher D,Oh S D .2015 .Concomitant Jak2 V617f-Positive polycythemia vera and Bcr-Abl-Positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J, 5(10) : E351-E351.